Chemotherapy for advanced gastric cancer

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 8, 2017, Pages

  Wagner, Anna Dorothea ^a   Syn, Nicholas L X ^b   Moehler, Markus ^c   Grothe, Wilfried ^d   Yong, Wei Peng ^b   Tai, Bee Choo ^e   Ho, Jingshan ^b   Unverzagt, Susanne ^d  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b National University Cancer Institute   (Singapore)

^c UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; IRINOTECAN; TAXOID;

ANALOGS AND DERIVATIVES; HUMAN; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); STOMACH NEOPLASMS;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CISPLATIN; FLUOROURACIL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STOMACH NEOPLASMS; TAXOIDS;

EID: 84941982813     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD004064.pub4     Document Type: Review

References (389)

1. Ajani JA, Fodor MB, Tjulandin SA, Moiseyenko VM, Chao Y, Cabral FS, et al. Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. Journal of Clinical Oncology 2005;23(24):5660-7. 2828581
2. Ajani JA, Buyse M, Lichinitser M, Gorbunova V, Bodoky G, Douillard JY, et al. Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. European Journal of Cancer 2013;49:3616-24. 2828583
3. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, et al. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. Journal of Clinical Oncology 2010;28(9):1547-53. 2828584
4. Bodoky G, Carrato A, Ravaioli A, Ajani JA. Quality of life in flags trial a randomized, comparative, open label, multicenter, phase 3 of S-1 + cisplatin (CS) compared to 5-fu + cisplatin (CF) in untreated advanced gastric cancer (AGC) patients. Annals of Oncology. 2012; Vol. 23 (Supplement 9):ix232-ix233. 6621025
5. Bodoky G, Scheulen ME, Rivera F, Jassem J, Carrato A, Moiseyenko V, et al. Clinical benefit and health-related quality of life assessment in patients treated with cisplatin/S-1 versus cisplatin/5-FU: secondary end point results from the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer 2015;46(2):109-17. 6621026
6. Al Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology 2008;26(9):1435-42. 2828586
7. Al-Batran SE, Pauligk C, Homann N, Hartmann JT, Moehler M, Probst S, et al. The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: a randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+). European Journal of Cancer 2013;49(4):835-42. 2828588
8. Kripp M, Al-Batran S E, Rosowski J, Pauligk C, Homann N, Hartmann JT, et al. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer 2014;17:181-7. 2828589
9. Barone C, Corsi DC, Pozzo C, Cassano A, Fontana T, Noviello MR, et al. Treatment of patients with advanced gastric carcinoma with a 5-fluorouracil-based or a cisplatin-based regimen: two parallel randomized phase II studies. Cancer 1998;82(8):1460-7. [MEDLINE: 12]2828591
10. Boku N, Yamamoto S, Fukuda H, Shirao K, Doi T, Sawaki A, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncology 2009;10(11):1063-9. 2828593
11. Boku N, Yamamoto S, Shirao K, Doi T, Sawaki A, Koizumi W, et al. Randomized phase III study of 5-fluorouracil (5-FU) alone versus combination of irinotecan and cisplatin (CP) versus S-1 alone in advanced gastric cancer (JCOG9912). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):LBA4513. 2828594
12. Bouche O, Raoul JL, Bonnetain F, Giovannini M, Etienne PL, Lledo G, et al. Randomized multicenter phase II trial of biweekly regime of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatinum, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer. Final results of study FFCD 9803. Journal of Clinical Oncology 2004;22:4319-29. 2828596
13. Cascinu S, Galizia E, Labianca R, Ferrau F, Pucci F, Silva RR, et al. Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology 2011;68(1):37-43. 2828598
14. Chen JH, Shen WX, Xia JX, Xu RL, Zhu MQ, Xu M. Comparative study between docetaxel, oxaliplatin plus S-1 and DCF regimen as first-line therapy in patients with advanced gastric cancer. Chinese Journal of Cancer Prevention and Treatment 2015;22(2):134-7. 6621028
15. Cocconi G, Bella M, Zironi S, Algeri R, Di Costanzo F, De Lisi V, et al. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. Journal of Clinical Oncology 1994;12(12):2687-93. [MEDLINE: 23]2828600
16. Cocconi G, Carlini P, Gamboni A, Gasperoni S, Rodino C, Zironi S, et al. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma. Annals of Oncology 2003;14(8):1258-63. [MEDLINE: 2]2828602
17. Colucci G, Giotta F, Maiello E, Cifarelli RA, Leo S, Giuliani F, et al. Efficacy of the association of folinic acid and 5-fluorouracil alone versus folinic acid and 5-fluorouracil plus 4-epidoxorubicin in the treatment of advanced gastric carcinoma. American Journal of Clinical Oncology 1995;18(6):519-24. [MEDLINE: 24]2828604
18. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma: fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA 1985;253:2061-7. 2828606
19. Cullinan SA, Moertel CG, Wieand HS, O'Connell MJ, Poon MA, Krook JE, et al. Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. Journal of Clinical Oncology 1994;12(2):412-6. [MEDLINE: 26]2828608
20. Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Quality of Life Research 2009;18:853-61. 2828610
21. Dank M, Zaluski J, Barone C, Valvere V, Yalcin S, Peschel C, et al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology 2008;19(8):1450-7. 2828611
22. De Lisi V, Cocconi G, Tonato M. Randomized comparison of 5-FU alone or combined with carmustine, doxorubicin, and mitomycin (BAFMi) in the treatment of advanced gastric cancer: a phase III trial of the Italian Clinical Research Oncology Group (GOIRC). Cancer Treatment Reports 1986;70:481-5. 2828613
23. Dong L, Li J, Lou XP, Miao JH, Lu P, Chang ZW, et al. Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. Journal of International Medical Research 2014;42(3):737-43. 6621030
24. Gastrointestinal Tumor Study Group. Triazinate and platinum efficacy in combination with 5-fluorouracil and doxorubicin: results of a three arm randomized trial in metastatic gastric cancer. Journal of the National Cancer Institute 1988;80:1011-5. 2828617
25. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with gastric cancer: a randomized study (START). Journal of Cancer Research and Clinical Oncology 2014;140:319-28. 2828618
26. Hironaka S, Sugimoto N, Yamaguchi K, Moriwaki T, Komatsu Y, Nishina T, et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial. Lancet Oncology 2016;17(1):99-108. [DOI: 10.1016/S1470-2045(15)00410-6]6621032
27. Huang D, Ba Y, Xiong Ji, Xu N, Yan Z, Zhuang Z, et al. A multicentre randomised trial comparing weekly paclitaxel+S-1 with weekly paclitaxel+5-fluorouracil for patients with advanced gastric cancer. European Journal of Cancer. England: Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin, China., 2013; Vol. 49, issue 14:2995-3002. 2828620
28. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non inferiority trial. Annals of Oncology 2009;20:666-73. [DOI: 10.1093/annonc/mdn717]2828622
29. Kikuchi K, Wakui A, Shimizu H, Kunii Y. Randomized controlled study on chemotherapy with 5-FU, ADM plus CDDP in advanced gastric carcinoma. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1990;17(4 Pt 1):655-62. [MEDLINE: 55]2828624
30. Kim TW, Choi SJ, Ahn JH, Bang HS, Chang HM, Kang YK, et al. A prospective randomized phase III trial of 5-fluorouracil and cisplatin (FP) versus epirubicin, cisplatin, and 5-fu (ECF) in the treatment of patients with previously untreated advanced gastric cancer (AGC). European Journal of Cancer 2001;37(Suppl 6):314. [MEDLINE: 56]2828626
31. Kim YS, Sym SJ, Park SH, Park I, Hong J, Ahn HK, et al. A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as firstline therapy for patients with advanced gastric cancer. Cancer Chemotherapy and Pharmacology 2014;73:163-9. 2828628
32. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncology 2008;9(3):215-21. 2828630
33. Fujii M. Chemotherapy for advanced gastric cancer: ongoing phase III study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study). International Journal of Clinical Oncology 2008;13(3):201-5. 2828633
34. Fujii M, Kim YH, Satoh T, Hosaka H, Kim T, Tsuji A, et al. Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update. Journal of Clinical Oncology 2011;29(15 Suppl 1):4016. 2828632
35. Kim YH, Koizumi W, Lee KH, Kishimoto T, Chung HC, et al. Randomized phase III study of S-1 alone versus S-1 plus Docetaxel in the treatment for advanced gastric cancer: The START trial. Journal of Clinical Oncology. 2011; Vol. 29:suppl. 4. 2828634
36. Koizumi W, Kim YH, Fujii M, Kim HK, Imamura H, Lee KH, et al. Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). Journal of Cancer Research and Clinical Oncology 2014;140(2):319-28. 6621033
37. Komatsu Y, Takahashi Y, Kimura Y, Oda H, Tajima Y, Tamura S. Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anti-cancer drugs 2011;22(6):576-83. 2828636
38. Kyoto Research Group for Chemotherapy of Gastric Cancer. A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4-epirubicin (FPEPIR). Anticancer Research 1992;12:1983-8. 2828638
39. Levi JA, Fox RM, Tattersall MH, Woods RL, Thomson D, Gill G. Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. Journal of Clinical Oncology 1986;4(9):1348-55. [MEDLINE: 70]2828640
40. Li Y, Zhu D. Comparison between the effect of SOX regimen and FOLFOX4 regimen for advanced gastric cancer. [Chinese]. Cancer Research and Clinic 2014;26(1):42-51. 6621035
41. Li YH, Qiu MZ, Xu JM, Sun GP, Lu HS, Liu YP, et al. S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study. Oncotarget 2015;6(33):35107-15. [DOI: 10.18632/oncotarget.5959]6621037
42. Li JY, Huang CZ, Yuan JH, Chen QH. Comparison of efficacy of modified EOX and FOLFIRI regimens in treatment of metastatic gastric cancer. World Chinese Journal of Digestology 2016;24(12):1866-73. 6621039
43. Loehrer PJ Sr, Harry D, Chlebowski RT. 5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. Investigational New Drugs 1994;12(1):57-63. [MEDLINE: 72]2828642
44. Lu Y, Liu Z, Zhang J. S-1 plus oxaliplatin vs. S-1 as first-line treatment in patients with previously untreated advanced gastric cancer: a randomized phase II study. Journal of Chemotherapy 2014;26(3):159-64. 6621041
45. Lutz MP, Wilke H, Wagener DJ, Vanhoefer U, Jeziorski K, Hegewisch-Becker S, et al. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology 2007;25(18):2580-5. 2828644
46. Moehler M, Eimermacher A, Siebler J, Höhler T, Wein A, Menges M, et al. Randomized phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) versus 5-fluorouracil, leucovorin and etoposide (ELF) in untreated metastatic gastric cancer. British Journal of Cancer 2005;92:2122-8. 2828646
47. Moehler M, Kanzler S, Geissler M, Raedle J, Ebert MP, et al. A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction. Annals of Oncology 2010;21:71-7. [DOI: 10.1093/annonc/mdp269]2828648
48. Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M. Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 1993;72(1):37-41. [MEDLINE: 77]2828650
49. Chin K, Iishi H, Imamura H, Kobayashi O, Imamoto H, Esaki T, et al. Irinotecan plus S-1 (IRIS) versus S-1 alone as first line treatment for advanced gastric cancer: Preliminary results of a randomized phase III study (GC0301/TOP-002). Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):4525. 2828652
50. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, et al. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011;14(1):72-80. 2828653
51. Morita S, Baba H, Tsuburaya A, Takiuchi H, Matsui T, Maehara Y, et al. A randomized phase II selection trial in patients with advanced/recurrent gastric cancer: Trial for Advanced Stomach Cancer (TASC). Japanese Journal of Clinical Oncology 2007;37(6):469-72. 2828655
52. Nishikawa K, Morita S, Matsui T, Kobayashi M, Takeuchi Y, Takahashi I, et al. A randomized phase-II trial comparing sequential and concurrent paclitaxel with oral or parenteral fluorinated pyrimidines for advanced or metastatic gastric cancer. Gastric Cancer 2012;15(4):363-9. 2828656
53. Ochenduszko S, Puskulluoglu M, Konopka K, Fijorek K, Urbanczyk K, Budzynski A, et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Medical Oncology 2015;32(10):242. [DOI: 10.1007/s12032-015-0687-7]6621043
54. Ocvirk J, Rebersek M, Skof E. Randomised prospective phase II study of combination chemotherapy epidoxorubicin, cisplatin, 5-FU (ECF) versus epidoxorubicin, cisplatin, capecitabin (ECX) in patients with advanced or metastatic gastric cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):4571. 2828659
55. Ocvirk J, Rebersek M, Skof E, Hlebanja Z, Boc M. Randomized prospective phase ii study to compare the combination chemotherapy regimen epirubicin, cisplatin, and 5-fluorouracil with epirubicin, cisplatin, and capecitabine in patients with advanced or metastatic gastric cancer. American Journal of Clinical Oncology 2012;35(3):237-41. 2828658
56. Ohtsu A, Shimada Y, Shirao K, Bouku N, Hyodo I, Saito H, et al. Randomized phase III trial of fluorouracil alone versus flourouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG 9205). Journal of Clinical Oncology 2003;21(1):54-9. [MEDLINE: 191]2828661
57. Popov I, Svetislav BJ, Jezdic SD. Bi-weekly 24-hour infusion of high dose 5-fluorouracil versus EAP regimen in advanced gastric cancer: a randomised phase II study. Annals of Oncology. 2002; Vol. 13 (Suppl. 5):188. [MEDLINE: 150]2828663
58. Popov IP, Jelic SB, Krivokapic ZV, Jezdic SD, Pesko PM, Micev MT, et al. Bimonthly 24 h infusion of high-dose 5-fluorouracil vs EAP regimen in patients with advanced gastric cancer. A randomized phase II study. Medical Oncology 2008;252(1):73-80. 2828664
59. Popov I, Radosevic-Jelic L, Jezdic S, Milovic M, Borojevic N, Stojanovic S, et al. Biweekly oxaliplatin, fluorouracil and leucovorin versus cisplatin, fluorouracil and leucovorin in patients with advanced gastric cancer. Journal of the Balkan Union of Oncology 2008;13(4):505-11. 2828666
60. Pyrhönen S, Kuitunen T, Nyandoto P, Kouri M. Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. British Journal of Cancer 1995;71(3):587-91. [MEDLINE: 92]2828668
61. Ridwelski K, Fahlke J, Schmidt C, Kettner E, Keilholz U, Quitzsch D, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: Preliminary results of a phase III study. Journal of Clinical Oncology 2008;26 (May 20 Suppl):Abstract 4512. 2828670
62. Ross P, Nicolson M, Cunningham D, Valle J, Seymour M, Harper P, et al. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology 2002;20(8):1996-2004. [MEDLINE: 137]2828672
63. Roth A, Kolaric K, Zupanc D, Oresic V, Roth A, Ebling Z. High doses of 5-fluorouracil and epirubicin with or without cisplatin in advanced gastric cancer: a randomized study. Tumori 1999;85(4):234-8. [MEDLINE: 96]2828674
64. Roth AD, Fazio N, Stupp R, Falk S, Bernhard J, Saletti P, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology 2007;25(22):3217-23. 2828676
65. Roy A, Cunningham D, Hawkins R, Sorbye H, Adenis A, Barcelo JR, et al. Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study. British Journal of Cancer 2012;107(3):435-41. 2828678
66. Sadighi S, Mohagheghi MA, Montazeri A, Sadighi Z. Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF). BMC Cancer 2006;6:274. 2828680
67. Scheithauer W, Kornek G, Hejna M, Depisch D, Raderer M, Huber H. Palliative chemotherapy versus best supportive care in patients with metastatic gastric cancer: a randomized trial. Annals of Hematology. 1996; Vol. 73 (Suppl 2):A181. [MEDLINE: 107]2828682
68. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized phase III study of 5-Fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG 0106). Japanese Journal of Clinical Oncology 2013;43(10):972-80. 2828684
69. Sugimoto N, Fujitani K, Imamura H, Uedo N, Iijima S, Imano M, et al. Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402). Anticancer Research 2014;34(2):851-7. 6621045
70. Thuss-Patience PC, Kretzschmar A, Repp M, Kingreen D, Henesser D, Micheel S, et al. Docetaxel and continuous infusion fluorouracil versus epirubicin, cisplatin and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. Journal of Clinical Oncology 2005;23(3):494-501. 2828686
71. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007;25:3205-9. 2828688
72. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007;25:3210-6. 2828689
73. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. Journal of Clinical Oncology 2006;24(31):4991-7. 2828690
74. Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, et al. Docetaxel plus oxaliplatin with or without fluorouracil pr capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Annals of Oncology 2015;26(1):149-56. 2828692
75. Wang X, Wang ML, Zhou LY, Lu XY, Yang JF, Yu HG. Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as first-line treatment in patients with advanced gastric cancer. Clinical and Translational Oncology. Springer Milan (Via Podgora 4, Milan I-20122, Italy), 2013; Vol. 15, issue 10:836-42. 2828694
76. Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer 2016;19(1):234-44. 6621047
77. Webb A, Cunningham D, Scarffe JH, Harper P, Norman A, Joffe JK, et al. Randomized trial comparing epirubicin, cisplatin, and fluouracil versus fluouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. Journal of Clinical Oncology 1997;15(1):261-7. [MEDLINE: 148]2828696
78. Wu D, Li X, Tong J, Sun L, Zheng H, Gao C, et al. S-1 combined with cisplatin versus cisplatin alone for the treatment of advanced gastric cancer: a pilot randomized-controlled trial. Anticancer Drugs 2015;26(7):774-8. [DOI: 10.1097/CAD.0000000000000242]6621049
79. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Annals of Oncology 2015;26:141-8. 2828698
80. Yamamura Y, Miyazaki I, Ogawa M, Yonemura Y, Tanemura H, Kito T, et al. A randomized controlled trial with methotrexate (MTX), 5-fluorouracil (5-FU) and pirarubicin (THP) vs 5-FU alone in advanced or recurrent gastric carcinoma. Tokai Hokuriku THP Study Group. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1998;25(10):1543-8. [MEDLINE: 132]2828700
81. Ahn JH, Kang YK, Kim TW, Bahng H, Chang HM, Kang WC, et al. Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. Cancer Chemotherapy & Pharmacology 2002;50(2):104-10. [MEDLINE: 2]2828702
82. Ajani JA. Docetaxel in combination for advanced gastric cancer. Gastric Cancer 2002;5(Suppl 1):31-4. [MEDLINE: 5]2828704
83. Ajani JA, Lee F-C, Singh DA, Haller DG, Lenz H-J, Benson Al B III, et al. Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric of gastroesophageal junction adenocarcinoma. Journal of Clinical Oncology 2006;24(4):663-7. 2828706
84. Akagi J, Baba H. PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients. International Journal of Clinical Oncology 2010;15(2):145-52. 2828708
85. Akazawa S, Nakajima T, Kitagawa H, Nakagawa T, Kanda Y, Futatsuki K, et al. Therapeutic effect of sequential doses of methotrexate (MTX) and 5-fluorouracil (5-FU) in advanced gastric cancer: comparison of intermediate-dose MTX with high-dose MTX. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1985;12(1):91-8. [MEDLINE: 140]2828710
86. Andrić Z, Randjelović T, Kovčin V, Gutović J, Crevar S, Murtezani Z, et al. Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer. Srpski Arhiv za Celokupno Lekarstvo 2012;140(5-6):305-12. 2828712
87. Anonymous. Phase II-III chemotherapy studies in advanced gastric cancer. The Gastrointestinal Tumor Study Group. Cancer Treatment Reports 1979;63(11-12):1871-6. [MEDLINE: 3]2828714
88. Anonymous. A comparative clinical assessment of combination chemotherapy in the management of advanced gastric carcinoma: The Gastrointestinal Tumour Study Group. Cancer 1982;49(7):1362-6. 6621051
89. O'Connel MJ, O'Fallon Y, Lavin PT, Moertel CG, Bruckner HW, Douglass HO Jr, et al. A comparative assessment of combination chemotherapy in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1980:Abstract 403. [MEDLINE: 85]6621052
90. Anonymous. Chemotherapy for advanced stomach cancer - a controlled study of AF and MF. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1983;10(10):2171-8. [MEDLINE: 5]2828716
91. Anonymous. Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. Cancer 1984;53(1):13-7. 6621054
92. O'Conell DM, Stablein DM for the Gastrointestinal Tumor Study Group. A prospective clinical trial of 5-fluorouracil/adriamycin based chemotherapy in unresectable gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1982; Vol. 2:91. [MEDLINE: 86]6621055
93. Aoyama M, Hirose H, Adachi N. Comparison of combination therapy of 5-fluorouracil, mitomycin C, and adriamycin (FAM) and mitomycin C, 5-fluorouracil and cytosine arabinoside (MFC) for advanced gastric cancer. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1981;8(5):757-62. [MEDLINE: 9]2828718
94. Bajetta E, Di Bartolomeo M, Carnaghi C, Buzzoni R, Mariani L, Gebbia V, et al. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. British Journal of Cancer 1998;77(7):1149-54. [MEDLINE: 10]2828720
95. Baker LH, Talley RW, Matter R, Lehane DE, Rutter BW, Jones SE, et al. Phase III comparison of the treatment of advanced gastrointestinal cancer with bolus weekly 5-FU vs. methyl-CCNU plus bolus weekly 5-FU. Cancer 1976;38:1-7. [MEDLINE: 163]2828722
96. Balana C, Camps C, Diaz Rubio E, Jimeno J, Dorta J, Massuti B, et al. Treatment of advanced gastric cancer (GC) with a fluorouracil (F) or a cisplatin (P) based chemotherapy. A study of the Spanish cooperative group for gastrointestinal tumor therapy (TTD). Annals of Oncology. 1990; Vol. 1 (Suppl):43. [MEDLINE: 11]2828724
97. Berenberg JL, Goodman PJ, Oishi N, Fleming T, Natale RB, Hutchins LH, et al. [5-Fluorouracil (5-FU) and folinic acid (FA): for the treatment of metastatic gastric cancer]. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1989; Vol. 8:101. 2828726
98. Berenberg JL, Tangen C, Macdonald JS, Hutchins LF, Natale RB, Oishi N, et al. Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group Study. Cancer 1995;76(5):715-9. [MEDLINE: 136]2828728
99. Beretta G, Fraschini P, Ravaioli A, Amadori D, Luporini G. FAM/FAMB Polychemotherapy for advanced carcinoma of the stomach (ACS): a randomized study. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1983; Vol. 2:131. [MEDLINE: 159]2828730
100. Beretta G, Arnoldi E, Beretta GD, Tedeschi L, Dallavalle G, Bollina R, et al. A randomized study of fluorouracil versus FAM polychemotherapy in gastric carcinoma. Proceedings of the EORTC Symposium on Advances in Gastrointestinal Tract Cancer Research and Treatment. Strasbourg, 1989:P.48. [MEDLINE: 162]2828732
101. Berglund A, Byström P, Pedersen D, Nygren P, Frödin JE, Bergman A, et al. GI-TAC: A randomised phase II study of sequential docetaxel and irinotecan with 5-fluorouracil.folinic acid in patients with metastatic upper abdominal (pancreatic, gastric or biliary) cancer. Annals of Oncology 2006;17(Suppl 9: Abstract 1126P):ix308-ix326. 2828734
102. Bi F, Li Q, Zhou C, Yu J, Cai X, Qiu M, et al. Preliminary results of a randomized phase II study: Treatment of Chinese patients with advanced gastric cancer with FOLFIRI followed by FOLFOX7 or the reverse sequence. Journal of Clinical Oncology. 2011; Vol. 29 (Supp 1):15. 2828736
103. Bjerkeset T, Fjosne HE. Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. Oncology 1986;43(4):212-5. [MEDLINE: 13]2828738
104. Bruckner HW, Stablein DM for the Gastrointestinal Tumor Study Group. A randomized study of 5-fluorouracil (F) and doxorubicin (A) with semustine (Me), cis-platinum (P), or triazinate (T) for treatment of advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1986; Vol. 5:90. [MEDLINE: 164]2828740
105. Brugarolas A, Garcia MM, Lacave AJ. Chemotherapy in advanced gastric cancer. A controlled clinical study. Proceedings /Annual Meeting of the American Association for Cancer Research. 1975; Vol. 16(66):169. [MEDLINE: 15]2828742
106. Bugat R. Irinotecan in the treatment of gastric cancer. Annals of Oncology 2003;14(Suppl 2):37-40. [MEDLINE: 13]2828744
107. Buroker T, Kim PN, Groppe C, McCracken J, O'Bryan R, Panettiere F, et al. 5 FU infusion with mitomycin-C vs. 5 FU infusion with methyl-CCNU in the treatment of advanced upper gastrointestinal cancer: a Southwest Oncology Group Study. Cancer 1979;44(4):1215-21. [MEDLINE: 16]2828746
108. Cai X, Xue P, Song WF, Hu J, Gu HL, Yang HY, et al. The role of pharmacokinetic monitoring of fluorouracil in improvement of efficacy and reduction of adverse reactions for patients with advanced gastric cancer. Tumor 2011;31(10):930-6. 2828748
109. Cascinu S, Cordella L, Catalano G. Neuroprotective effect of reduced glutathione (GSH) on cisplatin based chemotherapy in advanced gastric cancer: a double blind randomized trial. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1994; Vol. 13:431. [MEDLINE: 17]2828750
110. Cascinu S, Cordella L, Del Ferro E, Fronzoni M, Catalano G. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. Journal of Clinical Oncology 1995;13(1):26-32. [MEDLINE: 18]2828752
111. Cascinu S, Del Ferro E, Catalano G. Different doses of granulocyte colony stimulating factor to support a weekly chemotherapeutic regimen in advanced gastric cancer: a randomized study. Anti-Cancer Drugs 1996;7(1):43-7. [MEDLINE: 19]2828754
112. Chau I, Passalacqua R, Zalcberg JR, Fuchs CS, Liepa AM, Hsu Y, et al. Tolerability and quality-of-life (QoL) results from the phase 3 REGARD study: Ramucirumab versus placebo in patients with previously treated gastric or gastroesophageal junction (GEJ) adenocarcinoma. European Journal of Cancer. Elsevier Ltd, 2013; Vol. 49:S615. 2828756
113. Chen D, Jia R, Gao S, Feng X, Pan L, Song N, et al. Effect of low-dose gimeracil and oteracil potassium combined with oxaliplatin on aged patients with advanced gastric cardiac adenocarcinoma. Chinese Journal of Clinical Oncology 2011;38(7):396-9. 2828758
114. Chlebowski RT, Paroly WS, Pugh RP, Weiner JM, Bateman JR. Treatment of advanced gastric carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. Cancer Treatment Reports 1979;63(11-12):1979-81. [MEDLINE: 138]2828760
115. Chlebowski RT, Weiner JM, Silverberg I, Glass A, Bateman JR. Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. Oncology 1985;42(3):141-3. [MEDLINE: 20]2828762
116. Chu JH, Zhang Y, Liu DF, Ji HM. Weekly docetaxel combined with cisplatin of fluorouracil for advanced gastric carcinoma [Chinese]. Chinese Journal of Clinical Oncology 2006;11:541-2. 2828764
117. Chung KY, Saito K, Zergebel C, Hollywood E, Segal M, Saltz LB. Phase I study of two schedules of oral S-1 in combination with fixed doses of oxaliplatin and bevacizumab in patients with advanced solid tumors. Oncology 2011;8(2):65-72. 2828766
118. Coates AS, Tattersall MH, Swanson C, Hedley D, Fox RM, Raghavan D. Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. Journal of Clinical Oncology 1984;2(7):756-61. [MEDLINE: 21]2828768
119. Cocconi G, DeLisi V, Di Blasio B. Randomized comparison of 5-FU alone or combined with mitomycin and cytarabine (MFC) in the treatment of advanced gastric cancer. Cancer Treatment Reports 1982;66(6):1263-6. [MEDLINE: 22]2828770
120. Cocconi G, Bella M, Zironi S, Algeri R, Bartolucci R, De Lisi V, et al. A prospective randomized trial comparing FAM combination with PELF combination in advanced gastric carcinoma. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1992; Vol. 11:163. [MEDLINE: 166]2828772
121. Colucci G, Maiello E, Valori V, Pezzella G, Giuliani F. A randomized study with 5-FU + folinic acid (FA) alone or with epirubicin (E) in advanced gastric carcinoma. European Journal of Cancer. 1991; Vol. 27 Suppl. 2:S81. [MEDLINE: 168]2828774
122. Constenla M, Garcia-Arroyo R, Lorenzo I, Carrete N, Campos B, Palacios P. Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study. Gastric Cancer 2002;5(3):142-7. [MEDLINE: 7]2828776
123. Coombes RC, Chilvers CE, Amadori D, Medi F, Fountzilas G, Rauschecker H, et al. Randomised trial of epirubicin vs fluorouracil in advanced gastric cancer. An International Collaborative Cancer Group (ICCG) study. Annals of Oncology 1994;5:33-6. [MEDLINE: 189]2828778
124. Cullinan S, Moertel CG, Wieand H, Poon M. A randomized comparison of fluorouracil + adriamycin + cisplatin (FAP); fluorouracil + adriamycin + seumustine ( FAMe), FAME alternating with triazinate (T), and fluorouracil alone in advanced gastric carcinoma. A North Central Cancer Treatment Group Study. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1993; Vol. 12:200. [MEDLINE: 169]2828780
125. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. New England Journal of Medicine 2008;358:36-46. 2828782
126. De Lisi V, Tonato M, Leonardi F, Soldani M, Di Constanzo F, Marinelli G, et al. Randomized comparison of 5-fluorouracil (5-FU) versus a combination of BCNU (B), adriamycin (A), 5-FU and mitomycin C (Mi) (BAFMi) in the treatment of advanced gastric carcinoma. Proceedings/Annual Meeting of the American Association for Cancer Research. 1985; Vol. 26:696. [MEDLINE: 27]2828784
127. De Lisi V, Cocconi G, Tonato M, Di Costanzo F, Leonardi F, Soldani M. 5-Fluorouracil versus a combination of BCNU, adriamycin, 5-FU and mitomycin C in advanced gastric cancer: a prospective randomized study of the Italian Clinical Research Oncology Group. Recent Results in Cancer Research 1988;110:212-8. [MEDLINE: 29]2828786
128. Diaz-Rubio E, Jimeno J, Cervantes A, Cruz J, Camps C, Massutic B, et al. Treatment of stage IV gastric cancer (GC) with a fluorouracil (F) or a cisplatin (P) based combination chemotherapy. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1991; Vol. 10:158. [MEDLINE: 171]2828788
129. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. Phase II-III evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1983; Vol. 2:121. [MEDLINE: 161]2828790
130. Douglass HO Jr, Lavin PT, Goudsmit A, Klaassen DJ, Paul AR. An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). Journal of Clinical Oncology 1984;2(12):1372-81. [MEDLINE: 32]2828792
131. Duffour J, Bouche O, Rougier P, Milan C, Bedenne L, Seitz JF, et al. Safety of cisplatin combined with continuous 5-FU versus bolus 5-FU and leucovorin, in metastatic gastrointestinal cancer (FFCD 9404 randomised trial). Anticancer Research 2006;26(5B):3877-83. 2828794
132. Figoli F, Galligioni E, Crivellari D, Frustaci S, Talamini R, Sorio R, et al. Evaluation of two consecutive regimens in advanced gastric cancer. Cancer Investigation 1991;9(3):257-62. [MEDLINE: 34]2828796
133. Ford HER, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncology 2014;15(1):78-86. 2828798
134. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. REGARD Trial Investigators. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[DW11]. Lancet. England: Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address: cfuchs@partners.org., 2014; Vol. 383, issue 9911:31-9. 2828800
135. Fujii M, Murakami N. Single chemotherapy with 5-fluorouracil or ftorafur and combination chemotherapy with mitomycin C and 5-fluorouracil for inoperable elderly gastric cancers. [Japanese]. Nihon Gan Chiryo Gakkai Shi 1983;18(1):1-4. [MEDLINE: 36]2828804
136. Furue H, Uchino H, Orita K, Kimura T, Goto Y, Kondo T, et al. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer (the second report) - a randomized controlled study. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1985;12(6):1272-7. [MEDLINE: 37]2828806
137. Furukawa H, Iwanaga T, Nakajima T, Okabayashi K, Nakazato H, Hiratsuka M, et al. Randomized study with mitomycin C+ 5-fluorouracil+cytosine arabinoside (MFC)+5-fluorouracil, MFC + tegafur and uracil (UFT), and MF+UFT in advanced gastric cancer: Interinstitutional differences in a Multicenter Study in Japan. Journal of Surgical Oncology 1995;60(1):59-64. [MEDLINE: 38]2828808
138. Gao H, Ding X, Wei D, Xu T, Cheng P. Docetaxel versus epirubic in combined with cisplatin, leucovorin and fluorouracil for advanced gastric carcinoma as first line therapy: a randomized clinical trial. Chinese Journal of Clinical Oncology 2010;15:529-33. 2828810
139. Gioffre FM, Caputo G, Lucania L. 5-FU + BCNU versus FAM for advanced gastric cancer. [Italian]. Folia Oncologica 1984;7(3):198-203. [MEDLINE: 40]2828812
140. Glimelius B, Hoffman K, Haglund U. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Annals of Oncology 1994;5:189-90. [MEDLINE: 187]2828814
141. Glimelius B, Hoffman K, Graf W, Haglund U, Nyren O, Pahlman L, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Annals of Oncology 1995;6(3):267-74. [MEDLINE: 41]2828816
142. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Annals of Oncology 1997;8(2):1-6. [MEDLINE: 42]2828818
143. Goseki N, Maruyama M, Nagai K, Kando F, Endo M, Shimoju K, et al. Clinical evaluation of anticancer effect of methionine-depleting total parenteral nutrition with 5-fluorouracil and/or mitomycin C. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(8):1028-35. [MEDLINE: 43]2828820
144. Grau JJ, Estapé J, Alcobendas F, Gracía J, Antón A, Cruz JJ, et al. Mitomycin C-ftorafur versus mitomycin C alone as complementary chemotherapy in locally advanced gastric cancer. Neoplasia 1988;5:179-81. [MEDLINE: 45]2828822
145. Grieco A, Lasorella A, Astone A, Vagliviello L, Bartoloni C, Barone C. Chemotherapy of gastrointestinal cancer in the advanced stage with a combination of 5-fluorouracil, adriamycin, mitomycin C (FAM). A non-controlled study [Italian]. Clinica Terapeutica 1984;110(4):353-8. [MEDLINE: 46]2828824
146. Gubanski M, Johnsson A, Fernebro E, Kadar L, Karlberg I, Flygare P, et al. Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial. Gastric Cancer 2010;13(3):155-61. 2828826
147. Guimbaud R, Bouché O, Rebischung C, Bonnetain F, Louvet C, Viret F, et al. Planned interim analysis of the intergroup FFCD-GERCOR-FNCLCC-AERO phase III study comparing two sequences of chemotherapy in locally advanced or metastatic gastric cancers. Journal of Clinical Oncology 2009;210(15 suppl):4533. 2828828
148. Guimbaud R, Louvet C, Ries P, Ychou M, Maillard E, Andre T, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Federation Francophone de Cancerologie Digestive, Federation Nationale des Centres de Lutte Contre le Cancer, and Groupe Cooperateur Multidisciplinaire en Oncologie) study. Journal of Clinical Oncology 2014;32:3520-6. 2828829
149. Gupta S. Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C. Journal of Surgical Oncology 1982;21(2):94-6. [MEDLINE: 47]2828831
150. Haas C, Oishi N, Mc Donald B, Coltman C, O'Bryan R. Southwest Oncology Group Phase II-III Gastric Cancer Study: 5-fluorouracil, adramycin, and mitomycin-C +/- vincristine (FAM vs. V-FAM) compared to chlorozotozin (CZT), M-AMSA, and dihydroxyanthracenedione (DHAD) with unimpressive differences. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1983; Vol. 2:122. [MEDLINE: 157]2828833
151. Hawkins R, Cunningham D, Soerbye H, Adenis A, Canon J-L, Lopez-Vivanco G, et al. Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proceedings/Annual Meeting of the American Society of Clinical Oncology. 2003; Vol. 22:257. [MEDLINE: 154]2828835
152. Hoffman K, Glimelius B. Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer. Acta Oncologica 1998;37(7-8):651-9. [MEDLINE: 49]2828837
153. Icli F, Karaoguz H, Dincol D, Günel N. Comparison of EAP and FAM combination chemotherapies in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1993; Vol. 12:207. [MEDLINE: 160]2828839
154. Imada T, Sairenji M, Suda T, Yamamoto Y, Amano T, Motohashi H. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer. Hepato-Gastroenterology 1999;46(25):594-600. [MEDLINE: 51]2828841
155. Inoue Y, Nasu H, Nakamura J, Arakawa H, Masamune O, Yamada N, et al. Efficacy of UFT in advanced gastric carcinoma under comparative study of MMC + UFT and MMC + tegafur therapies. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1989;16(11):3567-72. [MEDLINE: 52]2828843
156. Jeung HC, Rha SY, Im CK, Shin SJ, Ahn JB, Yang WI, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy. Cancer 2011;117(10):2050-7. 2828845
157. Kang Y, Lee J, Min Y, Lee K, Zang D, Ryoo B, et al. A randomized multi-center phase II trial of capecitabine (X) versus S-1 (S) as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):4546. 2828847
158. Kelsen D, Atiq O, Niedzwiecki D. A random assignment trial of fluorouracil (F), methotrexate (MTX) and adriamycin (A) (FAMTX) versus etoposide, A, and cisplatin (P) (EAP) in gastric cancer (GAST CA). Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1990; Vol. 9:121. [MEDLINE: 172]2828849
159. Kilickap S, Yalcin S, Ates O, Tekuzman G. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fluorouracil (DCF) versus cisplatin and fluorouracil (CF); versus epirubicin, cisplatin and fluorouracil (ECF) regimens in clinical setting. Hepato-Gastroenterology 2011;58(105):208-12. 2828851
160. Kim NK, Park YS, Suh CI, Kang WK, Kim HT, Heo DS, et al. Phase III randomized comparison of 5-FU vs. FAM (5-FU/Adria/MMC) vs FP (5-FU/Cisplatin) in patients with advanced gastric carcinoma (AGC). Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1991; Vol. 10:144. [MEDLINE: 174]2828853
161. Kim NK, Park YS, Heo DS, Suh C, Kim SY, Park KC, et al. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Cancer 1993;71(12):3813-8. [MEDLINE: 57]2828855
162. Kim GM, Jeung HC, Rha SY, Kim HS, Jung I, Nam BH, et al. A randomized phase II trial of S-1-oxaliplatin versus capecitabine- oxaliplatin in advanced gastric cancer. European Journal of Cancer 2012;48(4):518-26. 2828857
163. Kim HS, Kim HJ, Kim SY, Lee KW, Baek SK, Kim TY, et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: A meta-analysis. Annals of Oncology. Oxford University Press (Great Clarendon Street, Oxford OX2 6DP, United Kingdom), 2013; Vol. 24, issue 11:2850-4. 2828861
164. Kitamura S, Ohtani T, Kurihara M, Kosaki G, Akazawa S, Sasaki T, et al. A controlled study of AO-90, a methionine-free intravenous amino acid solution, in combination with 5-fluorouracil and mitomycin C in advanced gastric cancer patients (internal medicine group evaluation). [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(6):765-75. [MEDLINE: 58]2828863
165. Koizumi W, Kurihara M, Hasegawa K, Chonan A, Kubo Y, Maekawa R. Combination therapy with cisplatin, 5'-deoxy-5-fluorouridine (5'-DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastric cancer: a randomized trial comparing two dosage regimens. Oncology Reports 1996;3(2):255-60. [MEDLINE: 62]2828867
166. Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, et al. Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer. Anticancer Research 2004;24(4):2465-70. 2828869
167. Koizumi W, Nakayama N, Tanabe S, Sasaki T, Higuchi K, Nishimura K, et al. A multicenter phase II study of combined chemotherapy with docetaxel, cisplatin, and S-1 in patients with unresectable or recurrent gastric cancer (KDOG 0601). Cancer Chemotherapy and Pharmacology 2012;69(2):407-11. 2828871
168. Koizumi W, Higuchi K, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin (BIRIP) versus irinotecan alone (IRI) after S-1-based chemotherapy failure in patients with advanced gastric cancer (AGC): Final analysis of a randomised phase III trial (TCOG GI-0801/BIRIP trial). European Journal of Cancer. Elsevier Ltd, 2013; Vol. 49:S616. 2828873
169. Kolaric K, Potrebica V, Stanovnik M. Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer. Oncology 1986;43(2):73-7. [MEDLINE: 149]2828875
170. Kondo K, Sakamoto J, Nakazato H, Koike A, Kitoh T, Hachisuka K, et al. A phase III randomized study comparing doxifluridine and 5-fluorouracil as supportive chemotherapy in advanced and recurrent gastric cancer. Oncology Reports 2000;7(3):485-90. [MEDLINE: 63]2828877
171. Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, et al. Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. Clinical Cancer Research 2002;8(6):1767-71. [MEDLINE: 10]2828879
172. Kornek GV, Raderer M, Schull B, Fiebiger W, Gedlicka C, Lenauer A, et al. Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer. British Journal of Cancer 2002;86(12):1858-63. [MEDLINE: 8]2828881
173. Kosaka T, Sugaya J, Yoshida S, Takano Y, Nakano Y, Akiyama T, et al. A study of chemotherapy for patients with severely advanced gastric cancer--comparison of chemotherapy and route [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(11):1582-5. [MEDLINE: 64]2828883
174. Kovach JS, Moertel CG, Schutt AJ, Hahn RG, Reitemeier J. A controlled study of combined 1, 3 bis (2 chloroethyl) 1 nitrosourea and 5 fluorouracil therapy for advanced gastric and pancreatic cancer. Cancer 1974;33:563. [MEDLINE: 65]2828885
175. Kuitunen T, Pyrhönen S. A randomized phase III trial comparing fluouracil, epidoxorubicin and methotrexate (FEMTX) with no treatment in nonresectable gastric cancer. European Journal of Cancer. 1991; Vol. 27 Supp. 2:80. [MEDLINE: 180]2828887
176. Kurihara M, Izumi T, Yoshida S, Ohkubo T, Suga S, Kiyohashi A, et al. A cooperative randomized study on tegafur plus mitomycin C versus combined tegafur and uracil plus mitomycin C in the treatment of advanced gastric cancer. Japanese Journal of Cancer Research 1991;82(5):613-20. 6621057
177. Ohkuwa M, Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, et al. Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. Gastric Cancer 2000;3(3):145-50. [MEDLINE: 88]6621058
178. Kurihara M, Kosaki G, Taguchi T, Akazawa S, Sasaki T, Takahashi H, et al. Quality of life in patients with advanced gastric cancer receiving AO-90, a methionine-free intravenous amino acid solution, with 5-fluorouracil and mitomycin C [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(7):911-23. [MEDLINE: 67]2828889
179. Kurihara M, Hasegawa K, Satoh A, Koizumi W, Saigenji K, Inoue S, et al. A randomized trial investigating two cisplatin (P) dosage schedules combined 5DFUR (D) and mitomycin C (M) for advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:214. [MEDLINE: 151]2828891
180. Lacave A, Dalesio O, Bleiberg H, Wils J, Diaz-Rubio E, Vendrik C, et al. A randomized trial of MeFA (methylccnu (Me); 5-fluorouracil (F), adriamycin (A)) vs. FA in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1985; Vol. 4:78. [MEDLINE: 176]2828893
181. Lacave A, Wils J, Bleiberg H, Diaz-Rubio E, Duez N, Dalesio O. An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer. Journal of Clinical Oncology 1987;5(9):1387-93. [MEDLINE: 68]2828895
182. Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, et al. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. British Journal of Cancer 2008;99(4):584-90. 2828897
183. Lee HJ, Park JC, Kim JH, Yoon JY, Cheoi KS, Lee H, et al. The ATP-based doublet chemotherapy response assay for un-resectable advanced gastric cancer; a single center, prospective, randomized controlled study. Gastrointestinal Endoscopy 2012;75 (4 Suppl 1):abstr. 236. 2828899
184. Levard H, Pouliquen X, Hay J-M, Fingerhut A, Langlois-Zantain O, Huguier M, et al. 5-fluorouracil and cisplatin as palliative treatment of advanced oesophageal squamous cell carcinoma: a multicentre randomised controlled trial. European Journal of Surgery 1998;164:849-57. [MEDLINE: 69]2828901
185. Li Q, Feng FY, Han J, Sui GJ, Zhu YG, Zhang Y, et al. Phase III clinical study of a new anticancer drug atofluding [Chinese]. Aizheng 2002;21(12):1350-3. [MEDLINE: 6]2828903
186. Li XQ, Gu HG, Guo JW, Zhu XX. Clinical study of continuous venous infusion of low-dose 5-Fu and cisplatin combined with weekly docetaxel for treatment of advanced gastric cancer [Chinese]. Modern Oncology 2007;15:659-61. 2828905
187. Li XD, Shen H, Jiang JT, Zhang HZ, Zheng X, Shu YQ, et al. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World Journal of Gastroenterology 2011;17(8):1082-7. 2828907
188. Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y, et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. Journal of Clinical Oncology 2013;31(26):3219-25. 2828909
189. Lim T, Yun J, Lee J, Park S, Park J, Park Y, et al. Updated survival results of the randomized phase II study comparing cisplatin/capecitabine (CX) with epirubicin plus CX (ECX) in advanced gastric cancer (AGC). Journal of Clinical Oncology 2011;29 (Supp 4):Abstract 46. 2828911
190. Livstone EM. A controlled randomized evaluation of combined modality therapy (5, 000 r+5-FU + MeCCNU versus combination chemotherapy (5-FU + Me CCNU) in the treatment of locally unresectable gastric carcinoma. Digestion 1977;16:256. [MEDLINE: 71]2828913
191. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncology 2013; Vol. 14, issue 6:490-9. 2828915
192. Lorenzen S, Hentrich M, Haberl C, Heinemann V, Schuster T, Seroneit T, et al. Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Annals of Oncology 2007;18(10):1673-9. 2828917
193. Luelmo S, Polee M, Van Bochove A, Pruijt H, Ouwerkerk J, Sleeboom H, et al. Randomized phase II study of cisplatin and highdose 5-fluorouracil/leucovorin or paclitaxel and high-dose 5-fluorouracil/leucovorinin locally advanced or metastatic gastric cancer and adenocarcinomas of the gastrooesophageal junction. Annals of Oncology 2006;17(Suppl 9: Abstract 530):ix308-ix326. 2828919
194. Malik STA, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PFM. Phase II trial of UFT in advanced colorectal and gastric cancer. British Journal of Cancer 1990;62(6):1023-5. [MEDLINE: 73]2828921
195. Maruta F, Ishizone S, Hiraguri M, Fujimori Y, Shimizu F, Kumeda S, et al. A clinical study of docetaxel with or without 5'DFUR as a second-line chemotherapy for advanced gastric cancer. Medical Oncology 2007;24(1):71-5. 2828923
196. Massuti B, Cervantes A, Anton A, Aranda E, Diaz-Rubio E, Abad A, et al. A phase III multicenter randomized study in advanced gastric cancer (GC): fluorouracil + leucovorin + epirubicin + cisplatin (FLEP) versus fluorouracil + adriamycin + methotrexate + leucovorin (FAMTX): toxicity report. Annals of Oncology 1994;5(Suppl 8):76. [MEDLINE: 139]2828925
197. Massuti B, Cervantes A, Aranda E, Abad A, Anton A, Jara C, et al. Myelotoxicity: the limiting side-effect of second-generation chemotherapy in gastric cancer: comparative analysis of fluorouracil + leucovorin + epirubicin + cisplatin (FLEP) and fluorouracil + adriamycin + methotrexate + leucovorin (FAMTX). Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:212. [MEDLINE: 177]2828927
198. Mochiki E, Ogata K, Ohno T, Toyomasu Y, Haga N, Fukai Y, et al. Phase II multi-institutional prospective randomised trial comparing S-1paclitaxel with S-1cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. British Journal of Cancer 2012;107(1):31-6. 2828929
199. Moertel CG, Mittelman JA, Bakemeier RF, Engstrom P, Hanley J. Sequential and combination chemotherapy of advanced gastric cancer. Cancer 1976;38(2):678-82. [MEDLINE: 74]2828931
200. Moertel CG, Engstrom P, Lavin PT, Gelber RD, Carbone PP. Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones". Surgery 1979;85(5):509-13. [MEDLINE: 75]2828933
201. Moertel CG, Lavin PT. Phase II-III chemotherapy studies in advanced gastric cancer. Eastern Cooperative Oncology Group. Cancer Treatment Reports 1979;63(11-12):1863-9. [MEDLINE: 76]2828935
202. Moore MJ. Three-armed trial to study new regimens for advanced gastric/esophageal cancer. Oncology Report 2005;SPRING:121-2. 2828937
203. Mustacchi G, Ceccherini R, Milani S, Sandri P, Leita ML, Carbonara T. Efficacy of sequential administration of G-CSF and GM-CSF after antitumor chemotherapy in patients with advanced cancer: Results of a randomized study. [Italian]. Tumori 1997;83(Suppl 5):S13-6. [MEDLINE: 78]2828939
204. Nakajima T, Takahashi T, Takagi K, Kuno K, Kajitani T. Comparison of 5-fluorouracil with ftorafur in adjuvant chemotherapies with combined inductive and maintenance therapies for gastric cancer. Journal of Clinical Oncology 1984;2(12):1366-71. [MEDLINE: 79]2828941
205. Nakao I, Uchino H, Orita K, Kaido I, Kimura T, Goto Y, et al. Clinical evaluation of schizophyllan (SPG) in advanced gastric cancer--a randomized comparative study by an envelope method. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1983;10(4 Pt 2):1146-59. [MEDLINE: 80]2828943
206. Nakashima K, Hironaka S, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, et al. Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution. Japanese Journal of Clinical Oncology 2008;38(12):810-5. 2828945
207. Niitani H, Kurihara M, Hasegawa K, Hatta Y, Suwa T, Tsuboi E, et al. Randomized comparison of continuous and intermittent oral administration of 5'-deoxy-5-fluorouridine in the treatment of advanced gastric cancer: a phase II trial by the multiinstitutional cooperative study group. [Japanese]. Japanese Journal of Cancer & Chemotherapy 1987;14(12):3345-50. [MEDLINE: 81]2828947
208. Nordin K, Steel J, Hoffman K, Glimelius B. Alternative methods of interpreting quality of life data in advanced gastrointestinal cancer patients. British Journal of Cancer 2001;85(9):1265-72. [MEDLINE: 83]2828949
209. Novik Y, Ryan LM, Haller DG, Asbury R, Dutcher JP, Schutt A. Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282. Medical Oncology 1999;16(4):261-6. [MEDLINE: 84]2828951
210. Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. Journal of Clinical Oncology 2011;29:3968-76. 2828959
211. Okines AFC, Asghar U, Cunningham D, Ashley S, Ashton J, Jackson K, et al. Rechallenge with platinum plus fluoropyrimidine +/- epirubicin in patients with oesophagogastric cancer. Oncology 2010;79(1-2):150-8. 2828961
212. Osawa S, Shiroto H, Kondo Y, Nakanishi Y, Fujisawa J, Miyakawa K, et al. Randomized controlled study on adjuvant immunochemotherapy with carmofur (HCFU) for noncuratively resected and unresected gastric cancer. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1996;23(3):327-31. [MEDLINE: 89]2828963
213. Pannettiere FJ, Haas C, McDonald B, Costanzi JJ, Talley RW, Athens J, et al. Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. Journal of Clinical Oncology 1984;2(5):420-4. [MEDLINE: 141]2828965
214. Park SH, Kim MJ, Chung M, Lee WK, Bang SM, Cho EK, et al. Interim analysis from a prospective randomized trial of taxanes plus 5-FU in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 2004; Vol. 23:360. 2828967
215. Park SH, Lee WK, Chung M, Lee Y, Han SH, Bang SM, et al. Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. Anti-Cancer Drugs 2006;17(2):225-9. 2828969
216. Park SH, Nam E, Park J, Cho EK, Shin DB, Lee JH, et al. Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer. Annals of Oncology 2008;19(4):729-33. 2828971
217. Popliela T, Zembala M, Oszacki J, Jedrychowski W. A follow-up study on chemoimmunotherapy (5-fluorouracil and BCG) in advances gastric cancer [abstract]. Cancer Immunology, Immunotherapy 1982;13:182-4. [MEDLINE: 90]2828973
218. Popov I, Jelic S, Radosavljevic D, Nicolic-Tomasevic Z. Eight-hour infusion versus bolus injection of doxorubicin in EAP regimen in patients with advanced gastric cancer (AGC): a prospective randomised trial. European Journal of Cancer 1999;35(Suppl 4):139. [MEDLINE: 178]2828975
219. Popov I, Jelic S, Radulovic S, Radosavljevic D, Nikolic TZ. Eight-hour infusion versus bolus injection of doxorubicin in the EAP regimen in patients with advanced gastric cancer: a prospective randomised trial. Annals of Oncology 2000;11(3):343-8. [MEDLINE: 91]2828977
220. Pozzo C, Barone C, Szanto J, Padi E, Peschel C, Bukki J, et al. Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study. Annals of Oncology 2004;15(12):1773-81. 2828979
221. Pyrhönen S, Kuitunen T, Kouri M. A randomized phase III trial comparing fluouracil, epidoxorubicin and methotrexate (FEMTX) with best supportive care in non-resectable gastric cancer. Annals of Oncology 1992; Vol. 3, issue Suppl 5:47. [MEDLINE: 179]2828981
222. Queisser W, Schnitzler G, Heim ME, Konig H, Katz R, Fritze D, et al. Prospective randomized study in advanced stomach cancer. Comparison between combinations of 5-fluorouracil and carmustine without and with adriamycin [Prospektiv randomisierte studie beim fortgeschrittenen magenkarzinom]. Deutsche Medizinische Wochenschrift (1946) 1984;109(25):976-80. 6621060
223. Schnitzler G, Queißer W, Heim ME, König HJ, Fritze D, Herrmann R, et al. Comparison of 5-FU-BCNU (FB) and 5-FU/adriamycin/BCNU (FAB) in advanced gastric cancer [Vergleich von 5-Fluorouracil-BCNU (FB) mit 5-Fluorouracil-Adriamycin-BCNU (FAB) beim fortgeschrittenen Magenkarzinom]. Verhandlungen der Deutschen Gesellschaft fur Innere Medizin 1983;89:105-4. 6621061
224. Rake MO, Mallinson CN, Cocking JB, Cwynarski MT, Fox CA, Wass VJ, et al. Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study. Gut 1979;20(9):797-801. [MEDLINE: 94]2828983
225. Roth A, Kolaric K, Zupanc D. High doses of epirubicin and 5-fluorouracil with or without cisplatin in advanced gastric cancer - a preliminary report of a randomized study. Libri Oncologici 1994;23:187-93. [MEDLINE: 95]2828985
226. Roth A, Kolaric K, Zupanc D. High doses of epirubicin and 5-fluouracil with or without cisplatin in advanced gastric cancer. European Journal of Cancer. 1995; Vol. 31A (Suppl 5). [MEDLINE: 182]2828987
227. Roth A, Zupanc D. Randomised clinical study (phase III) FE versus FEP in advanced gastric cancer. European Journal of Cancer. 1997; Vol. 33 (Suppl 8):275. [MEDLINE: 181]2828989
228. Sakata Y, Yoshida Y, Komatsu Y, Sugawara K, Nishimura S, Kikuchi K. MQF-OK therapy in advanced terminal stomach cancer-with special reference to a comparison with MFC therapy. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1982;9(1):109-15. [MEDLINE: 97]2828991
229. Sakata Y, Munakata A, Baba T, Saitoh S, Itoh T, Tamura Y, et al. Controlled study of MQF-OK therapy with FT and with UFT on various advanced gastrointestinal cancers. Hirosaki Cooperative Study Group of Cancer Chemotherapy. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1988;15(7):2065-71. [MEDLINE: 98]2828993
230. Sakata Y, Chiba Y, Sato T, Kimura M, Fukushi G, Matsukawa M, et al. Comparative study of UFT plus mitomycin C and UFT plus doxorubicin in adenocarcinoma. Hirosaki Cooperative Group of Cancer Chemotherapy. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1992;19(2):195-201. [MEDLINE: 99]2828995
231. Sasagawa T, Ho N, Endo T, Sekine T, Sugiyama K, Tomidokoro T, et al. Randomized controlled trial of MMC + UFT and MMC + 5-FU therapy in advanced gastric cancer. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1994;21(8):1179-85. [MEDLINE: 100]2828997
232. Sasaki T, Ota K, Ibayashi J, Sakata Y, Matsuoka T, Ishikawa M. Randomized multicenter trial of sequential methotrexate and 5-fluorouracil versus 5-fluorouracil alone in advanced gastric cancer. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1989;16(8 Pt 1):2545-55. [MEDLINE: 102]2828999
233. Sasaki T, Ota K, Sakata Y, Matsuoka T, Wakui A, Akazawa S, et al. High-dose leucovorin and 5-fluorouracil in advanced gastric and colorectal cancer. High-Dose Leucovorin and 5-FU Study Group. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1990;17(12):2361-8. [MEDLINE: 103]2829001
234. Sasaki T. High-dose leucovorin and 5-FU. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1992;19(7):954-62. [MEDLINE: 101]2829003
235. Sasaki T. Clinical evaluation of leucovorin and 5-fluorouracil. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(8):1001-8. [MEDLINE: 104]2829005
236. Sato H, Wakui A, Hoshi M, Kurihara M, Yokoyama M, Shimizu H. Randomized controlled trial of induced hypertension chemotherapy (IHC) using angiotensin II human (TY-10721) in advanced gastric carcinoma (TY-10721 IHC Study Group Report). [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1991;18(3):451-60. [MEDLINE: 105]2829007
237. Sato H, Sugiyama K, Hoshi M, Urushiyama M, Ishizuka K. Angiotensin II (AII) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging. World Journal of Surgery 1995;19(6):836-42. [MEDLINE: 106]2829009
238. Satoh T, Doi T, Tsuji A, Omuro Y, Miwa H, Nishina T, et al. A Japanese subgroup analysis of the lapatinib for gastric cancer (TyTAN) study. Annals of Oncology. Oxford University Press, 2013; Vol. 24:ix6. 2829011
239. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study. Journal of Clinical Oncology 2014;32:2039-49. 2829013
240. Schmid KE, Kornek GV, Schull B, Raderer M, Lenauer A, Depisch D, et al. Second-line treatment of advanced gastric cancer with oxaliplatin plus raltitrexed. Onkologie 2003;26(3):255-8. [MEDLINE: 1]2829015
241. Shen YC, Chu JH. Observation of weekly dose of docetaxel combined with small doses of cisplatin, 5-fluorouracil continuous intravenous infusion treatment of advanced gastric cancer [Chinese]. Journal of Basic and Clinical Oncology 2009;22(4):318-20. 2829019
242. Shin D, Lee S, Park S, Park J, Cho E, Lee J, et al. Randomized phase II trial of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) for advanced gastric cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):4580. 2829021
243. Shinoda M, Morise K, Kusugami K, Iwase H, Ina K, Kaneko H. Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1995;22(4):515-20. [MEDLINE: 109]2829023
244. Sun H, Qun Z, Guifang L. Clinical study of 68 advanced gastric cancer cases treated by DELF project. Zhejiang Oncology 1999;5:85-6. [MEDLINE: 110]2829025
245. Shudong X, Dehua L, Dezong Z. ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group. [Chinese]. Chung-Hua Chung Liu Tsa Chih [Chinese Journal of Oncology] 1996;18(1):30-3. [MEDLINE: 129]2829027
246. Smith BJ, Ashford RF, Bakowski M, Hellman K, Newton K, Phillips R, et al. A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. American Journal of Clinical Oncology 1983;6(4):481-4. [MEDLINE: 111]2829029
247. Sun W, Whittington R, Gallagher M, O'Dwyer P, Giantonio B, Metz J, et al. Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma. Oncology (Williston Park) 2004;18(14 (Suppl 14)):39-42. 2829031
248. Sym SJ, Hong J, Park J, Cho EK, Lee JH, Park YH, et al. A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy. Cancer Chemotherapy and Pharmacology 2013; Vol. 71, issue 2:481-8. 6621063
249. Taal BG, ten Bokkel Huinink WW, Simonetti G, Franklin H, McVie JG. A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer. Cancer Investigation 1990;8(5):501-4. [MEDLINE: 112]2829033
250. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Itoh I, et al. Results of phase III study of lentinan. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1985;12(2):366-78. [MEDLINE: 113]2829035
251. Takahashi N. 5-FU concentration in the tissue of gastric cancer, and evaluation of cancer chemotherapy with angiotensin-II. [Japanese]. Nihon Geka Gakkai Zasshi 1991;92(7):775-84. [MEDLINE: 114]2829037
252. Tebbutt NC, Norman A, Cunningham D, Iveson T, Seymour M, Hickish T, et al. A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer. Annals of Oncology 2002;13(10):1568-75. [MEDLINE: 115]2829039
253. Tebbutt N, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, et al. ATTAX: Randomised phase II study evaluating weekly docetaxel-based chemotherapy combinations in advanced esophago- gastric cancer, final results of an AGITG trial. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings Part I 2007;25(18S):4528. 2829041
254. Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, et al. Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 2010;102:475-81. 2829043
255. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). European Journal of Cancer 2011;47(15):2306-14. 2829045
256. Thuss-Patience PC, Kretzschmar A, Deist T, Hinke A, Bichev D, Lebedinzew B, et al. Irinotecan versus best supportive care (BSC) as second-line therapy in gastric cancer: a randomized phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Journal of Clinical Oncology 2009;27(15s):abstr 4540. 2829046
257. Tsushima K, Sakata Y, Suzuki H, Saitoh S, Sugimoto N, Itoh T, et al. A randomized controlled study of 5-fluorouracil/doxorubicin/mitomycin C/OK-432 (FAM-OK) therapy and 4-fluorouracil/epirubicin/mitomycin C/OK-432 (FEM-OK) therapy in advanced gastric cancer. Journal of Japan Society for Cancer Therapy 1991;26(7):1317-24. [MEDLINE: 118]2829048
258. Van Cutsem E, Kang Y, Chung H, Shen L, Sawaki L, Lordick F, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Journal of Clinical Oncology Supplement 2009;27:abstr LBA4509. 2829050
259. Vanhoefer Uk, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, et al. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. Journal of Clinical Oncology 2000;18(14):2648-57. 6621065
260. Wilke H, Wils J, Rougier P, Lacave A, Van Cutsem E, Vanhoefer U, et al. Preliminary analysis of a randomized phase III trial of FAMTX versus ELF versus cisplatin/5-FU in advanced gastric cancer (GC): a trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group and the AIO (Arbeitsgemeinschaft Internsitische Onkologie). Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:206. [MEDLINE: 184]6621066
261. Vaughn CB, Brady P, Chinn BJ. Combination chemotherapy in advanced gastrointestinal malignancy (with 1 color plate). Oncology 1980;37(1):57-61. [MEDLINE: 120]2829052
262. Vestlev PM, Pedersen H. Doxorubicin and 5-fluorouracil versus doxorubicin and oral ftorafur in the treatment of advanced gastric cancer - a phase II and III trial. Acta Oncologica 1990;29(7):945-6. [MEDLINE: 121]2829054
263. Villar A, Asensio F, Candel M, Delgado F, Garcia J, Lledo S, et al. Chemotherapy of advanced gastric carcinoma (stage IV): a randomized study of FAM versus 5-FU plus BCNU. Chemioterapia 1987;6(1):57-62. [MEDLINE: 122]2829056
264. Voznyi EK, Borisov VI, Perevodchikova NI, Babaian LA, Vaarik KhM. Comparative assessment of the effectiveness of the preparations CCNU, 5-fluorouracil, ftorafur and their combinations in inoperable stomach cancer [Russian]. Vestnik Akademii Meditsinskikh Nauk SSSR 1978;9:83-7. [MEDLINE: 123]2829058
265. Wadler S, Brain C, Catalano P, Einzig AI, Cella D, Benson AB, III. Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: Eastern Cooperative Oncology Group Study E6296. Cancer Journal 2002;8(3):282-6. [MEDLINE: 9]2829060
266. Wakui A, Takahashi K, Sato Y, Sato K, Matsuoka T, Saito T. Clinical evaluation of chemoimmunotherapy for advanced gastrointestinal cancer using a combined regimen of 5-fluorouracil, adriamycin and levamisole. [Japanese]. Gan to Kagaku Ryoho [Japanese Journal of Cancer & Chemotherapy] 1983;10(2):218-26. [MEDLINE: 124]2829062
267. Wakui A, Kikuchi K, Yokoyama M, Takahashi K, Yoshida Y, Kaito I, et al. Phase III multi-center study of levamisole (LMS)--a randomized evaluation in advanced gastrointestinal cancer, with special reference to stomach cancer. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1983;10(7):1610-23. [MEDLINE: 125]2829064
268. Wakui A, Kasai M, Konno K, Abe R, Kanamaru R, Takahashi K, et al. Randomized study of lentinan on patients with advanced gastric and colorectal cancer. Tohoku Lentinan Study Group. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1986;13 (4 part 1):1050-9. [MEDLINE: 126]2829066
269. Wang ZH, Chen Z, Li CZ, Zhou DG, Sheng LJ, Liu B, et al. Comparative study of continuous intravenous infusional tegafur or 5-fluorouracil combined with oxaliplatin in the treatment of advanced gastric cancer. Chinese Journal of Cancer Prevention and Treatment 2007;14(2):136-9. 2829068
270. Waters JS, Norman A, Cunningham D, Scarffe JH, Webb A, Harper P, et al. Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. British Journal of Cancer 1999;80(1-2):269-72. [MEDLINE: 127]2829070
271. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncology 2014;15:1224-35. 2829074
272. Klein HO, Buyse M, Wils JA. Prospective randomized trial using 5-fluorouracil, adriamycin and methotrexate (FAMTX) versus FAM for treatment of advanced gastric cancer. Onkologie 1992;15(5):364-7. [MEDLINE: 61]6621068
273. Wils J, Klein H, Bleiberg H, Buyse M, Wagener DTh, Diaz-Rubio E, et al. EORTC 40851: A Gastrointestinal Group (GI) randomized evaluation of the toxicity of sequential high-dose methotrexate (MTX) and 5-fluouracil (F) combined with adriamycin (A) (FAMTX) versus F, A and mitomycin C (M) (FAM) in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1987; Vol. 6:73. [MEDLINE: 190]6621069
274. Wils J, Klein HO, Bleiberg H, Buyse M, Wagener DJ, Conroy T, et al. EORTC 40851: Sequential high dose methotrexate (MTX) and 5-fluorouracil (F) combined with adriamycin (A) (FAMTX versus F, A, and mitomycin C (M) (FAM) in advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1989; Vol. 8:109. [MEDLINE: 186]6621070
275. Wils J, Klein HO, Bleiberg H, Buyse M, Wagener DJTh, Conroy T, et al. FAMTX (5-FU, adriamycin (A) and methotrexate (MTX)): a step ahead in the treatment of advanced gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 1990; Vol. 9, issue 102. [MEDLINE: 175]6621071
276. Wils JA, Klein HO, Wagener DJ, Bleiberg H, Reis H, Korsten F, et al. Sequential high-dose methotrexate and fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. Journal of Clinical Oncology 1991;9(5):827-31. 6621072
277. Wils J, Wagener DJT, Coombes RC, Fountzilas G, Bliss JM, Law M, et al. Phase III trial of fluorouracil, methotrexate and epirubicin (FEMTX) versus FEMTX plus cisplatin (FEMTX-P) in advanced gastric cancer. Annals of Oncology. 1994; Vol. 5 (Suppl 8). [MEDLINE: 144]2829082
278. Xu R, Ma N, Wang F, Ma L, Chen R, Chen R, et al. Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer. OncoTargets and Therapy 2013;6:925-9. 2829084
279. Yamada Y, Tsushima K, Sakata Y, Saito S, Ito T, Sugimoto N, et al. Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy. [Japanese]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 1994;21(7):1029-32. [MEDLINE: 130]2829086
280. Yin Zheng-Min, Zhang Y, Xie Zhong. Elemene plus fluorouracil in the treatment of advanced gastric cancer. [Chinese]. Chinese Journal of Clinical Oncology 1996;23(11):810-12. [MEDLINE: 134]2829098
281. Yoshida K, Tanabe K, Ueno H, Ohta K, Hihara J, Toge T, et al. Future prospects of personalized chemotherapy in gastric cancer patients: results of a prospective randomized pilot study. Gastric Cancer 2003;6(Suppl 1):82-9. [MEDLINE: 3]2829088
282. Yoshikawa T, Tsuburaya A, Saze Z, Aoyama T, Hasegawa S, Kanemoto A, et al. [Randomized phase II trial to compare S-1 and S-1/PSK for advanced or recurrent gastric cancer-lessons from the results]. Gan to Kagaku Ryoho. Cancer & Chemotherapy 2011; Vol. 38, issue 12:1909-11. 2829090
283. Yoshino S, Oka M. Randomized phase III study of S-1 alone versus S-1 plus lentinan in advanced or recurrent gastric cancer. Biotherapy 2007;21(5):315-21. 2829092
284. Yun J, Park SH, Park JO, Park YS, Ho YL, Kang WK. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. European Journal of Cancer 2010;46:885-91. 2829094
285. Zhao F, Wang Q, Zhang JW, Hang M, Chen SB. Therapeutic evaluation of docetaxel-combined chemotherapy for advanced gastric carcinoma [Chinese]. Acta Universitatis Medicinalis NanJing (Natural Science) 2009;29:237-9. 2829096
286. Zironi S, Cocconi G, Bella M, Algeri R, Bartolucci R, De Lisi V, et al. A prospective randomized trial comparing FAM combination in advanced gastric carcinoma. Annals of Oncology. 1992; Vol. 3 (Suppl 5):13. [MEDLINE: 165]2829100
287. Elsaid AA, Elkerm Y. Final results of a randomized phase III trial of docetaxel, carboplatin and 5FU versus epirubicin, cisplatin and 5FU for locally advanced gastric cancer. Journal of Clinical Oncology, ASCO Annual Meeting Proceedings 2005;23(16S):4014. 2829103
288. Higuche K, Koizumi W, Yamada Y, Nishikawa K, Gotoh M. Randomized phase III study of S-1 plus oxaliplatin versus S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Journal of Clinical Oncology. 2012; Vol. 30 (suppl. 34):abstr 60. 2829105
289. Isovorin: Phase III study. Ongoing study - .
290. Maiello E, De Vita F, Gebbia V, Lorusso S, Cinieri S, Giuliani F, et al. Epirubicin (E) in combination with cisplatin (CDDP) and capecitabine (C) versus docetaxel (D) combined with 5-fluorouracil (5-FU) by continuous infusion as front-line therapy in patients with advanced gastric cancer (AGC): Preliminary results of a randomized phase II trial of the Gruppo Oncologico Dell'Italia Meridionale. Journal of Clinical Oncology 2011;29(suppl 1):97. 2829108
291. NCT01498289. S1201: Combination chemo for oatients w/advanced or metastatic esophageal, gastric, or gastroesophageal junction cancer. clinicaltrials.gov/ct2/show/NCT01498289 Dat first received: 22 December 2011. 6621073
292. NCT01558947. Peri-operative chemotherapy with ECX or XP in the treatment of advanced gastric cancer. clinicaltrials.gov/ct2/show/NCT01558947 Date first received: 7 March 2012. 6621075
293. NCT01967875. A phase 2 trial of optimizing platinum-based chemotherapy based on ERCC1 expression as first-line treatment in patients with locally advanced or metastatic gastric cancer. clinicaltrials.gov/ct2/show/NCT01967875 Date first received: 15 October 2013. 6621076
294. NCT02076594. Low-Tox vs Eox in patients with locally advanced unresectable or metastatic gastric cancer. clinicaltrials.gov/ct2/show/NCT02076594 Date first received: 20 August 2013. 6621078
295. NCT02114359. Chemotherapy options for the first line chemotherapy in elderly patient with advanced gastric cancer. clinicaltrials.gov/ct2/show/NCT02114359 Date first received: 9 April 2014. 6621080
296. NCT02289378. Dose-dense biweekly docetaxel, oxaliplatin and 5-fluorouracil as first-line treatment in advanced gastric cancer (DaeMon-Plus). clinicaltrials.gov/ct2/show/NCT02289378 Date first received: 7 November 2014. 6621082
297. NCT02289547. Phase 3 study of Xelox followed by maintenance capecitabine in the advanced gastric cancer. clinicaltrials.gov/ct2/show/NCT02289547 Date first received: 30 October 2014. 6621083
298. NCT02549911. HIPEC, intravenous chemotherapy and surgery for the treatment of advanced GC with peritoneal metastasis. clinicaltrials.gov/ct2/show/NCT02549911 Date first received: 7 September 2015. 6621085
299. NCT02583659. The first-line combined chemotherapy for advanced gastric cancer: a prospective observational clinical study. clinicaltrials.gov/ct2/show/NCT02583659 Date first received: 19 October 2015. 6621087
300. NCT02855788. Metronomic chemotherapy in advanced gastric cancer. clinicaltrials.gov/ct2/show/NCT02855788 Date first received: 2 August 2016. 6621089
301. NCT03006432. Phase iii randomised trial to evaluate folfox with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma (GASTFOX). clinicaltrials.gov/ct2/show/NCT03006432 Date first received: 27 December 2016. 6621091
302. Tsuburaya A, Morita S, Kodera Y, Kobayashi M, Shitara K, Yamaguchi K, et al. A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II). BMC Cancer 2012;12:307. 2829114
303. Abrams JA, Gonsalves L, Neugut AI. Diverging trends in the Incidence of reflux-related and Helicobacter pylori-related gastric cardia cancer. Journal of Clinical Gastroenterology 2013;47(4):322-7.
304. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007;25:3205-9.
305. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group. Journal of Clinical Oncology 2007;25:3210-6.
306. Al-Batran SE, Ajani JA. Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer. Cancer 2010;116(11):2511-8.
307. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncology 2016;17(12):1697-708.
308. Altman DG. Systematic reviews of evaluations of prognostic variables. In: Egger M, et al. editor(s). Systematic Reviews in Health Care. 2nd Edition. London: BMJ, 2001:228-47.
309. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376(9742):687-97.
310. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012/01/10 2012; Vol. 379, issue 9813:315-21. [0140-6736]
311. Bonenkamp JJ, Hermanns J, Sasako M. Extended lymph-node dissection for gastric cancer. New England Journal of Medicine 1999;340:908-14.
312. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4th Edition. Lyon (France): IARC Press, 2010. [9283224329]
313. Chan DY, Syn NL, Yap R, Phua JN, Soh TI, Chee CE, et al. Conversion surgery post-intraperitoneal paclitaxel and systemic chemotherapy for gastric cancer carcinomatosis peritonei. Are we ready?. Journal of Gastrointestinal Surgery 2017;21(3):425-33. [DOI: 10.1007/s11605-016-3336-3; NCT01739894]
314. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases 1987;40(5):373-83.
315. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer - pooled analysis from three multicenter, randomized, controlled trials using individual patient data. Journal of Clinical Oncology 2004;22(12):2395-403.
316. Chen XL, Chen XZ, Yang C, Liao YB, Li H, Wang L, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis. PLOS One 2013;8:e60320.
317. Correa P. Helicobacter pylori and gastric cancer: state of the art. Cancer Epidemiology, Biomarkers & Prevention 1996;5:477-81.
318. Crew CD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Seminars in Oncology 2004;31(4):450-61.
319. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. New England Journal of Medicine 2006;355(1):11-20.
320. Curran D, Pozzo C, Zaluski J, Dank M, Barone C, Valvere V, et al. Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. Quality of Life Research 2009;18:853-61.
321. Digklia A, Wagner AD. Advanced gastric cancer: Current treatment landscape and future perspectives. World Journal of Gastroenterology 2016;22(8):2403-14.
322. Dixon M, Mahar AL, Helyer LK, Vasilevska-Ristovska J, Law C, Coburn NG. Prognostic factors in metastatic gastric cancer: results of a population-based, retrospective cohort study in Ontario. Gastric Cancer 2016;19(1):150-9.
323. Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. Journal of Clinical Oncology 2014;32:1277-80.
324. Eremenco SL, Cashy J, Webster K, Ohashi Y, Locker GY, Pelletier G, et al. FACT-Gastric: a new international measure of QOL in gastric cancer. Proceedings/Annual Meeting of the American Society of Clinical Oncology. 2004; Vol. 23.
325. Ferrell BR, Temel JS, Temin S, Alesi ER, Balboni TA, Basch EM, et al. Integration of palliative care into standard oncology care: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology 2017;35(1):96-112.
326. Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, et al. Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. European Journal of Cancer 2014;50(7):1330-44.
327. Garrido M, Fonseca PJ, Vieitez JM, Frunza M, Lacave AJ. Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer. Expert Review of Anticancer Therapy 2014;14(8):887-900.
328. GASTRIC Group, Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, et al. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. European Journal of Cancer 2013;49(7):1565-77.
329. Global Burden of Disease Cancer Collaboration. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology 2017;3(4):524-48.
330. Higgings JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
331. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008. Available from www.cochrane-handbook.org.
332. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
333. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New England Journal of Medicine 2004;350(23):2335-42.
334. Ilson DH. Docetaxel, cisplatin and fluouracil in gastric cancer: does the punishment fit the crime?. Journal of Clinical Oncology 2007;25(22):3188-90.
335. Jadad AR, Moore A, Carroll D. Assessing the quality of reports of randomized clinical trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
336. Kang JH, Lee SI, Lim DH, Park K-W, Oh SY, Kwon H-C, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. Journal of Clinical Oncology 2012; Vol. 30, issue 13:1513-8. [0732-183X]
337. Kang Y-K, Shah MA, Ohtsu A, Van Custem E, Ajani JA, van der Horst T, et al. A randomized, open-label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T-DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2-positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). Journal of Clinical Oncology 2016;4S:abstr 5. [http://meetinglibrary.asco.org/record/120278/abstract]
338. Kang Y-K, Satoh T, Ryu M-H, Chao Y, Kato K, Chung HC, et al. Nivolumab (ONO-4538/BMS-936558) as salvage treatment after second or later-line chemotherapy for advanced gastric or gastro-esophageal junction cancer (AGC): A double-blinded, randomized, phase III trial. Journal of Clinical Oncology 2017;35(4S):abstract 2. [http://meetinglibrary.asco.org/record/139096/abstract]
339. Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner A D, et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer 2017;1 February:Epub ahead of print.
340. Kelley JR, Duggan JM. Gastric cancer epidemiology and risk factors. Journal of Clinical Epidemiology 2003;56:1-9.
341. Kripp M, Al-Batran S E, Rosowski J, Pauligk C, Homann N, Hartmann JT, et al. Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Gastric Cancer 2014;17:181-7. 2828589
342. Lauren P. The two histological main types of gastric carcinoma: an attempt at a histological classification. Acta Pathologica Microbiologica Scandinavia 1965;64:31-49.
343. Leichman L, Berry BT. Cisplatin therapy for adenocarcinoma of the stomach. Seminars in Oncology 1991;18 (1 Suppl 3):25-33.
344. Lordick F, Allum W, Carneiro F, Mitry E, Tabernero J, Tan P, et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treatment Reviews 2014;40:692-700.
345. Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus?. Gastric Cancer 2014;17:213-25.
346. MacDonald JS, Havlin KA. Etoposide in gastric cancer. Seminars in Oncology 1992;19 (6 Suppl 13):59-62.
347. MacDonald JS. Gastric cancer. Educational Book. ASCO, 2001:77-80.
348. MacDonald JS, Smalley SR, Benedetti J. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New England Journal of Medicine 2001;345:725-30.
349. Machin D, Stenning SP, Parmar MKP. Thirty years of Medical Research Council randomized trials in solid tumors. Journal of Clinical Oncology 1997;9:100-14.
350. Moher D, Liberati A, Tetzlaff J, Altman DG, the PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Medicine 2009;6(7):1-6.
351. Munoz N, Correa P, Cuello C. Histological types of gastric carcinoma in high and low risk areas. International Journal of Cancer 1968;3:809-18.
352. Muro K, Chung H C, Shankaran V, Geva R, Catenacci D, Gupta S, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncology 2016;17(6):717-26.
353. Norman GR, Sloan J, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Medical Care 2003;41(5):582-92.
354. Ohkuwa M, Ohtsu A, Boku N, Yoshida S, Miyata Y, Shirao K, et al. Long-term results for patients with unresectable gastric cancer who received chemotherapy in the Japan Clinical Oncology Group (JCOG) trials. Gastric Cancer 2000;3(3):145-50. [MEDLINE: 88]2828957
355. Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. Journal of Clinical Oncology. 2013/09/18 2013; Vol. 31, issue 31:3935-43. [0732-183x]
356. Okines A, Chau I, Cunningham D. Capecitabine in gastric cancer. Drugs of Today 2008;44(8):629-40.
357. Pallis AG, Ring A, Fortpied C, Penninckx B, Van Nes MC, Wedding U, et al. EORTC workshop on clinical trial methodology in older individuals with a diagnosis of solid tumors. Annals of Oncology 2011;22(8):1922-6.
358. Paoletti X, Oba K, Bang YJ, Bleiberg H, Boku N, Bouche O, et al. Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis. Journal of the National Cancer Institute 2013;105(21):1667-70.
359. Parmar MKB, Torri V, Steward L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
360. Peleteiro B, La Vecchia C, Lunet N. The role of Helicobacter pylori infection in the web of gastric cancer causation. European Journal of Cancer Prevention 2012;21(2):118-25.
361. Petrelli F, Zaniboni A, Coinu A, Cabiddu M, Ghilardi M, Sgroi G, et al. Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis. PLOS One 2013;8:e83022.
362. Preusser P, Achterrath W, Wilke H, Lenaz L, Fink U, Heinicke A, et al. Chemotherapy of gastric cancer. Cancer Treatment Reviews 1988;15:257-77.
363. Pye JK, Crumplin MK, Charles J. One-year survey of carcinoma of the esophagus and stomach in Wales. British Journal of Surgery 2001;88:278-85.
364. Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
365. Rusch VW. Are cancers of the esophagus, gastroesophageal junction, and cardia one disease, two, or several?. Seminars in Oncology 2004;31(4):444-9.
366. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. New England Journal of Medicine 2007;357(18):1810-20.
367. Sepulveda C, Marlin A, Yoshida T, Ulrich A. Palliative care: the World Health Organization's global perspective. Journal of Pain and Symptom Management 2002;24(2):91-6.
368. Sharma P. Cancer of the esophagogastric junction: epidemiology and pathogenesis. Journal of Gastrointestinal Surgery 2003;6:516-7.
369. Song H, Zhu J, Lu D. Molecular-targeted first-line therapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2016, Issue 7. [DOI: 10.1002/14651858.CD011461.pub2]
370. Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology 2010;11:439-49.
371. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. New England Journal of Medicine 2015;372(8):724-34.
372. Syn NL, Yong WP, Lee SC, Goh BC. Genetic factors affecting drug disposition in Asian cancer patients. Expert Opinion on Drug Metabolism & Toxicology 2015;11(12):1879-92. [DOI: 10.1517/17425255.2015.1108964]
373. Syn NL, Yong WP, Goh BC, Lee SC. Evolving landscape of tumor molecular profiling for personalized cancer therapy: a comprehensive review. Expert Opinion on Drug Metabolism & Toxicology 2016;12(8):911-22. [DOI: 10.1080/17425255.2016.1196187]
374. Tan IB, Ivanova T, Lim KH, Ong CW, Deng N, Lee J, et al. Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy. Gastroenterology 2011;141:476-85, e1-11.
375. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
376. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. New England Journal of Medicine 2010;363(8):733-42.
377. Thompson SG, Higgins JB. How should meta-regression analysis be undertaken and interpreted?. Statistics in Medicine 2002;21(11):1559-73.
378. Tierney JF, Stewart L, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007;8:16.
379. Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. New England Journal of Medicine 2012;367(19):1783-91.
380. Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. European Journal of Cancer 2001;37(8):966-71.
381. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nature Reviews. Clinical Oncology 2013;10(11):643-55.
382. Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, et al. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. Journal of Clinical Oncology 2013;31(29):3711-8.
383. Wu AH, Wan P, Bernstein L. A multiethnic population-based study of smoking, alcohol and body size and risk of adenocarcinomas of the stomach and esophagus (United States). Cancer Causes & Control 2001;12:721-32.
384. Wu-Williams AH, Yu MC, Mack TM. Lifestyle, the workplace and stomach cancer by subsite in young men of Los Angeles County. Cancer Research 1990;50:2569-76.
385. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. Journal of Clinical Oncology. 2011/03/30 2011; Vol. 29, issue 13:1715-21. [0732-183x]
386. Wagner AD, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD004064]
387. Wagner ADW, Grothe W, Behl S, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI: 10.1002/14651858.CD004064.pub2]
388. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE, et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. Journal of Clinical Oncology 2006;24:2903-6.
389. Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J, et al. Chemotherapy for advanced gastric cancer. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD004064.pub3]